Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia
NCT06664125
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
50
Enrollment
INDUSTRY
Sponsor class
Conditions
Hyperphosphatemia
Interventions
DRUG:
JMKX003002 will be administered orally
DRUG:
Sevelamer carbonate
Sponsor
Jemincare